Harrow Shares Rise 6.8% Despite Wider Q1 Losses, 2026 Revenue Outlook Reaffirmed

Harrow Reassures Investors with 2026 Outlook Despite Q1 Headwinds

Harrow, Inc. ($HROW) shares advanced 6.8% to $15.65 on May 15, 2026, despite the ophthalmic pharmaceutical company reporting a wider net loss of $12.5 million for the first quarter ended March 31, 2026. This loss compares to an $8.2 million net loss in the prior-year period. The company also saw its revenue decrease by 15% year-over-year, falling to $22.1 million from $26.0 million in Q1 2025.

The positive market reaction, which saw trading volume spike over 150% above its 30-day average, signaled investor confidence in management's reaffirmed guidance for fiscal year 2026. Harrow reiterated its full-year revenue projection of $200 million to $215 million, alongside an adjusted EBITDA forecast of $90 million to $105 million. This forward-looking stability overshadowed the immediate quarterly performance, where the diluted loss per share widened to $0.45 from $0.30 in Q1 2025.

Market Impact

Harrow's stock closed at $15.65, marking its largest single-day percentage gain since November 2025, when the company announced a significant product acquisition. The shares traded within a range of $14.80 to $15.92 during the session, pushing the company's market capitalization to approximately $482 million from $451 million the previous day. Daily trading volume reached 2.8 million shares, significantly surpassing the 30-day average of 1.1 million shares, indicating strong institutional and retail interest.

This upward movement for $HROW stands in contrast to a broader pharmaceutical sector that saw modest gains, with the $XPH SPDR S&P Pharmaceuticals ETF rising just 0.7% on the same day. The rally suggests that investors are increasingly valuing Harrow's long-term growth strategy, particularly its pipeline of ophthalmic products and recent acquisitions, over short-term profitability fluctuations. Historically, $HROW has been sensitive to guidance updates, with previous reaffirmations often leading to positive price action, even amidst mixed quarterly results. The stock has now recovered approximately 12% from its year-to-date low of $13.90 reached in February 2026.

What Analysts Are Saying

Analysts largely interpreted the market's reaction as a vote of confidence in Harrow's strategic direction and its ability to execute on its 2026 guidance. "Despite the headline loss, the reaffirmed full-year outlook is the critical takeaway here," stated Michael Chen, a senior analyst at J.P. Morgan. "Harrow's management has consistently emphasized their path to profitability is back-half weighted in 2026, driven by new product launches and the full integration of recent acquisitions. The market is clearly buying into that narrative."

Conversely, some analysts remain cautious regarding the immediate financial health. "While the reaffirmation is positive, the widening net loss and revenue decline cannot be ignored," noted Sarah Thompson, an equity analyst at Stifel Financial. "Sustained losses raise questions about cash burn and the company's ability to fund its ambitious growth plans without further dilution or debt. We maintain a 'Hold' rating until we see concrete evidence of improved operational efficiency and revenue growth in subsequent quarters."

A third perspective from Wells Fargo analysts highlighted the importance of adjusted EBITDA as a better indicator of underlying performance. "Harrow's adjusted EBITDA of $3.5 million for Q1, though lower than Q1 2025's $5.8 million, still provides a clearer picture of operational cash flow before non-cash charges," explained David Lee, a biotech equity strategist at Wells Fargo. "The market's focus on the $90 million to $105 million adjusted EBITDA guidance for 2026 indicates a belief in the company's ability to scale operations and improve margins significantly as new products gain traction."

What to Watch

Investors will be closely monitoring several key factors that could influence $HROW's trajectory in the coming quarters. The company's Q2 2026 earnings report, expected in early August 2026, will be crucial for demonstrating progress towards its reaffirmed annual guidance. Specific attention will be paid to revenue growth from newer products and any improvements in gross margins.

Further updates on the commercialization of Harrow's recently acquired ophthalmic products, particularly those targeting glaucoma and dry eye, will also be pivotal. Any successful market penetration or positive physician adoption rates could provide significant catalysts for sustained revenue growth. Conversely, slower-than-expected uptake or increased competition could pressure the company's ability to meet its 2026 targets.

Technically, the stock faces immediate resistance at the $16.00 level, a psychological barrier that has proven difficult to breach in recent months. A sustained break above this point could open the path towards $17.50, a level last seen in late 2025. On the downside, the $14.50 mark serves as a critical support level; a breach below this could signal renewed bearish sentiment.

Risk factors include continued pressure on legacy product sales, potential delays in regulatory approvals for pipeline assets, and the ongoing challenge of managing operating expenses while investing heavily in growth initiatives. Investors should also watch for any changes in the competitive landscape for ophthalmic pharmaceuticals, which could impact Harrow's market share and pricing power.